Drugs / HN2302
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07523282 | Apr 2026 → Dec 2027 expected | systemic lupus erythematosus, systemic sclerosis | Shenzhen MagicRNA Biotechnology Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07413835 | Mar 2026 → Jun 2027 expected | myasthenia gravis | The Affiliated Hospital of Xuzhou Medical University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HN2302 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07523282 ↗ |
| Modality | Cell therapy | “in vivo CAR-T” NCT07523282 ↗ |